![ibrutinib-with-chemoimmunotherapy-improved-progression-free-survival-for-newly-diagnosed-mantle-cell-lymphoma-patients](https://utterbuzz.com/wp-content/uploads/2022/06/ibrutinib-with-chemoimmunotherapy-improved-progression-free-survival-for-newly-diagnosed-mantle-cell-lymphoma-patients-640x360.jpg)
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers reported.